SALEM, Mass., Sept. 29 /PRNewswire/ -- LaVoie Group, a full-service provider of public relations, investor relations, corporate communications, and marketing strategy to life science clients, today announced that it has been selected as public relations agency of record by cancer therapeutics company, Neotropix(R), Inc.
Donna L. LaVoie, President & CEO of LaVoie Group, commented, "We are delighted to represent Neotropix during an important stage in the company's clinical development. Neuroendocrine cancers are difficult to treat and Neotropix has developed an innovative treatment approach that warrants further clinical development and financing. We look forward to working with the Company to communicate its message to appropriate investors, media, pharmaceutical partners and physicians."
Neotropix(R), Inc., is focused on the development of anti-cancer products that have a high degree of selectivity for tissues resulting in both therapeutic efficacy and an excellent safety and tolerability profile. Neotropix(R) develops and commercializes systemically deliverable oncolytic viruses for the treatment of solid tumors. Capitalizing on its unique sources of naturally occurring viruses that selectively target tumors discovered using the company's proprietary technology platform Viruscreen(TM), the Company has the knowledge and skills to translate these discoveries into commercial products. Neotropix(R) is committed to making a difference in the lives of cancer patients.
Neotropix(R) commenced operations in 2005 in Malvern, Pennsylvania and is venture-capital-funded company by investors including Aurora Funds, Quaker BioVentures and VIMAC Ventures. For more information, please visit http://www.neotropix.com .
About LaVoie Group, Inc.
LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position, create visibility and drive value for each client. Our clients range from privately held start-ups to industry leaders in life sciences. For more information, please visit http://www.lavoiegroup.com.
|SOURCE LaVoie Group|
Copyright©2008 PR Newswire.
All rights reserved